Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
This agreement is part of Vect-Horus’ strategy to leverage its technological platform by entering into research and product development agreements with pharmaceutical and biopharmaceutical companies to generate patentable new chemical entities (NCEs) based on its partner’s drug or imaging candidates.
“We are proud to have signed this agreement with a European leader in Molecular Nuclear Medicine,” said Alexandre Tokay, co-founder of Vect-Horus. “We believe that this scientific collaboration will be fruitful for both parties and open new avenues in the treatment of brain diseases.”
"We find Vect-Horus’ technology very interesting and see real potential in Molecular Nuclear Diagnostics," said Stefano Buono, CEO of AAA.